{"id":"mycoph-nolate-mof-til","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)"},{"rate":"20-30","effect":"Leukopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"15-25","effect":"Infection"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MMF is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant isoform in activated lymphocytes. This blocks guanosine nucleotide synthesis required for lymphocyte DNA replication, thereby reducing T and B cell proliferation without affecting other cell types as severely. It is used as an immunosuppressant to prevent organ transplant rejection and treat autoimmune conditions.","oneSentence":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:37.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ transplant rejection (renal, cardiac, hepatic)"},{"name":"Active lupus nephritis"},{"name":"Autoimmune conditions requiring immunosuppression"}]},"trialDetails":[{"nctId":"NCT06881927","phase":"PHASE4","title":"Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-02-01","conditions":"Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients","enrollment":212},{"nctId":"NCT00456235","phase":"PHASE4","title":"Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2006-09","conditions":"Liver Transplantation","enrollment":92},{"nctId":"NCT00538265","phase":"PHASE4","title":"Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2005-05","conditions":"Liver Transplantation","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13076,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mycophénolate Mofétil","genericName":"Mycophénolate Mofétil","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent immune rejection. Used for Prevention of acute organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants, Treatment of active lupus nephritis, Treatment of autoimmune conditions including rheumatoid arthritis and other systemic autoimmune diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}